Is EVLO or SMFL more profitable?

Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Smart for Life N/A N/A N/A

Is EVLO or GNCA more profitable?

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Which has stronger valuation and earnings, EVLO or PXMD?

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evelo Biosciences N/A N/A -$114.53M -$8.81 N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is EVLO or PXMD more profitable?

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Evelo Biosciences N/A N/A N/A PaxMedica N/A -3,167.89% -560.35%

Which has higher earnings & valuation, GNCAQ or EVLO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genocea Biosciences N/A N/A N/A N/A N/A Evelo Biosciences N/A N/A -$114.53M -$8.81 N/A

Is GNCAQ or EVLO more profitable?

Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A N/A N/A Evelo Biosciences N/A N/A N/A

Is SYRS or EVLO more profitable?

Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Syros Pharmaceuticals N/A -3,369.56% -97.04% Evelo Biosciences N/A N/A N/A

Evelo Biosciences (EVLO) Competitors

$0.0001 0.00 (0.00%)

As of 06/12/2026 03:56 PM Eastern

Compare

EVLO vs. SMFL, GNCA, PXMD, GNCAQ, and SYRS

Should you buy Evelo Biosciences stock or one of its competitors? MarketBeat compares Evelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evelo Biosciences include Smart for Life (SMFL), Genocea Biosciences (GNCA), PaxMedica (PXMD), Genocea Biosciences (GNCAQ), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry.

How does Evelo Biosciences compare to Smart for Life?

Evelo Biosciences (NASDAQ:EVLO) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Smart for Life has higher revenue and earnings than Evelo Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Smart for Life	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Smart for Life	N/A	N/A	N/A

Evelo Biosciences has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Smart for Life has a beta of 14.81, indicating that its share price is 1,381% more volatile than the broader market.

Summary

Smart for Life beats Evelo Biosciences on 5 of the 7 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
Genocea Biosciences	Neutral

Summary

Genocea Biosciences beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to PaxMedica?

Evelo Biosciences (NASDAQ:EVLO) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Evelo Biosciences	Neutral
PaxMedica	Neutral

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evelo Biosciences	N/A	N/A	N/A
PaxMedica	N/A	-3,167.89%	-560.35%

Evelo Biosciences has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Evelo Biosciences	Neutral

0.3% of Evelo Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Evelo Biosciences	N/A	N/A	N/A

Genocea Biosciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A

Summary

Genocea Biosciences and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Evelo Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Evelo Biosciences	Neutral

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Evelo Biosciences	N/A	N/A	N/A

Evelo Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A
Evelo Biosciences	N/A	N/A	-$114.53M	-$8.81	N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Evelo Biosciences beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVLO vs. The Competition

Export

Metric	Evelo Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2K	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.45	24.00	24.42
Price / Sales	N/A	120.49	533.77	123.88
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	7.85	10.55	6.82
Net Income	-$114.53M	-$4.88M	$3.57B	$337.56M
7 Day Performance	N/A	0.64%	0.59%	1.16%
1 Month Performance	N/A	-0.16%	1.55%	3.16%
1 Year Performance	N/A	47.51%	25.41%	30.60%

Evelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVLO Evelo Biosciences	N/A	$0.00 flat	N/A	N/A	$2K	N/A	N/A	120
SMFL Smart for Life	N/A	$0.00 flat	N/A	-93.2%	$7K	$11.11M	N/A	110	High Trading Volume
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	+600.0%	$6K	N/A	N/A	2	Gap Down
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evelo Biosciences (EVLO) Competitors

EVLO vs. SMFL, GNCA, PXMD, GNCAQ, and SYRS

How does Evelo Biosciences compare to Smart for Life?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Summary

How does Evelo Biosciences compare to PaxMedica?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Summary

How does Evelo Biosciences compare to Syros Pharmaceuticals?

Summary

Media Sentiment Over Time

EVLO vs. The Competition

Evelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evelo Biosciences (EVLO) Competitors

EVLO vs. SMFL, GNCA, PXMD, GNCAQ, and SYRS

How does Evelo Biosciences compare to Smart for Life?

Which has preferable valuation and earnings, EVLO or SMFL?

Do insiders and institutionals have more ownership in EVLO or SMFL?

Does the media refer more to EVLO or SMFL?

Is EVLO or SMFL more profitable?

Which has more risk and volatility, EVLO or SMFL?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Which has better earnings and valuation, EVLO or GNCA?

Is EVLO or GNCA more profitable?

Do institutionals and insiders have more ownership in EVLO or GNCA?

Which has more volatility & risk, EVLO or GNCA?

Does the media prefer EVLO or GNCA?

Summary

How does Evelo Biosciences compare to PaxMedica?

Which has stronger valuation and earnings, EVLO or PXMD?

Does the media favor EVLO or PXMD?

Is EVLO or PXMD more profitable?

Which has more risk & volatility, EVLO or PXMD?

Do insiders & institutionals believe in EVLO or PXMD?

Summary

How does Evelo Biosciences compare to Genocea Biosciences?

Does the media prefer GNCAQ or EVLO?

Do insiders & institutionals believe in GNCAQ or EVLO?

Is GNCAQ or EVLO more profitable?

Which has more volatility & risk, GNCAQ or EVLO?

Which has higher earnings & valuation, GNCAQ or EVLO?

Summary

How does Evelo Biosciences compare to Syros Pharmaceuticals?

Does the media favor SYRS or EVLO?

Which has more risk & volatility, SYRS or EVLO?

Is SYRS or EVLO more profitable?

Which has better earnings and valuation, SYRS or EVLO?

Do institutionals and insiders hold more shares of SYRS or EVLO?

Summary

Media Sentiment Over Time

EVLO vs. The Competition

Evelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools